Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Cai Y, Chen M, Gong Y, Tang G, Shu Z, Chen J, et al
MEDI0382,a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a singledose, healthysubject, randomized, phase 1 study
Ive talked about the upsides of pharmacologically boosting GLP-1 activity in terms of weight loss, given the ravages of obesity, and Ive also discussed its downsides, including common gastrointestinal reactions and muscle loss, as well as the rarer or more speculative side effects such as thyroid cancer, pancreatitis, and pancreatic cancer
Key Points Tirzepatide is approved for weight loss, type 2 diabetes, and sleep apnea Healthcare providers start tirzepatide at 2.5 mg weekly and increase the dose gradually every 4 weeks to minimize side effects Higher doses of tirzepatide may produce greater weight loss results and lower blood sugar levels, but individual results vary Studies show that tirzepatide works better combined with diet and lifestyle changes Tirzepatide, available as Mounjaro and Zepbound, has shown impressive results in clinical trials with 15-20% weight loss, improved A1C levels for people with type 2 diabetes, and even benefits for sleep apnea
2015 Apr 30;10(4):e0123861
